Avita Reaffirms $80M-$85M Guidance on RECELL, Cohealyx Data

Biotechnology firm Avita Medical on May 14, 2026, reaffirmed its fiscal year 2026 revenue guidance of $80 million to $85 million. The company attributes its confidence to the ongoing normalization of insurance reimbursement for its flagship RECELL System and promising clinical data for its Cohealyx platform. This announcement provides investors with a stable outlook on the company's commercial ramp-up for its innovative skin regeneration technologies.

Why is Avita Confident in its Revenue Target?

Avita's management reiterated its financial forecast, signaling a clear path toward its medium-term commercial goals. The guidance of $80 million to $85 million for the fiscal year ending in 2026 is a critical benchmark for the growth-stage company. This projection is built on the expanding adoption of its core product in burn and wound care centers.

The primary driver behind this confidence is the stabilization of reimbursement pathways for the RECELL System. This technology, which uses a small sample of a patient's own skin to create Spray-On Skin™ Cells, depends on consistent payments from insurers. Predictable reimbursement, with procedure codes now more firmly established, reduces financial uncertainty for hospitals, encouraging wider adoption and driving Avita's top-line growth.

The company's commercial sales have already shown momentum, with total revenue for the quarter ending March 31, 2024, reaching $14.1 million. The reaffirmed guidance suggests management expects this growth trajectory to accelerate significantly over the next two fiscal years, underpinned by deeper market penetration in the United States.

How Does Cohealyx Strengthen the Product Pipeline?

Beyond its established RECELL system, Avita is developing its Cohealyx platform to improve wound treatment outcomes. Recent data for Cohealyx, designed as a pre-grafting treatment to stabilize wound beds, points toward the ability to achieve graft readiness faster. This is a crucial clinical and economic advantage for healthcare providers.

By preparing the wound bed more effectively, Cohealyx could reduce the time between injury and definitive treatment with a skin graft. This has the potential to shorten average hospital stays, a key metric for burn centers managing costs and patient throughput. The company is targeting a meaningful reduction in preparation time, potentially by more than 25% in certain cases.

This pipeline development complements the RECELL system, creating a more integrated wound care solution. A combined protocol using both Cohealyx and RECELL could offer a superior standard of care, making Avita's technology suite more compelling to its target market of specialized surgical centers. This overlap is a core component of the company's long-term growth strategy within the healthcare sector.

What is Avita's Market Position and Financial Health?

Avita Medical operates in the competitive advanced wound care market, which is valued at over $12 billion globally. The company's innovative approach to skin regeneration positions it as a disruptive force against traditional skin grafting methods, which can be more painful and require larger donor skin sites.

With a market capitalization of approximately $350 million, Avita is still a small-cap player. Its financial profile is typical of a company in a high-growth phase, with increasing revenues but ongoing operating losses due to heavy investment in research, development, and commercial expansion. For the most recent fiscal year, the company reported a net loss as it scaled its operations.

One significant risk for investors is the company's reliance on the RECELL system for the vast majority of its current revenue. While the Cohealyx pipeline is promising, any setbacks in its development or a slowdown in RECELL adoption could materially impact the company's ability to meet its stated revenue guidance. Diversifying its product offerings and indications is critical for long-term stability.

Q: What specific conditions does the RECELL System treat?

A: The RECELL System is FDA-approved for several indications. Its primary uses are for treating acute thermal burn wounds in patients 18 years and older and for repigmentation of stable depigmented vitiligo lesions. It is also approved for treating full-thickness skin defects, expanding its application beyond burns to other complex wounds requiring surgical intervention.

Q: Is Avita Medical currently profitable?

A: No, Avita Medical is not yet profitable on a GAAP basis. The company is in a commercial growth phase, investing heavily in its sales force, marketing, and research and development for new products like Cohealyx. In its most recent fiscal year, the company reported a net loss of over $30 million as it focused on scaling its business and capturing market share.

Q: Where is Avita Medical's stock traded?

A: Avita Medical holds a dual listing. Its primary listing is on the NASDAQ Global Market in the United States under the ticker symbol RCEL. It is also listed on the Australian Securities Exchange (ASX) under the ticker symbol AVH, reflecting its origins as an Australian company.

Bottom Line

Avita Medical's reaffirmed 2026 guidance signals strong confidence in its commercial execution, hinging on RECELL adoption and a promising product pipeline.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.